Table 2.

Abundance of NG2, PDGFR alpha, CD11b, and PDGFR beta expressing cells in wild type and NG2 null mice 1, 2, and 6 weeks after lysolecithin injection.

		NG2 (%)	PDGFRα (%)	CD11b (%)	PDGFRβ (%)
Sham	WT	6.12 ± 1.7c	8.32 ± 2.1c	-	6.62 ± 0.9c
	KO	-	6.77 ± 2.6c	-	4.82 ± 1.4c
1W	WT	100 ± 8.2	100 ± 11.5	100 ± 9.1	100 ± 17.7
	KO	-	72.69 ± 16.8*	33.23 ± 10.3***	60.59 ± 15*
2W	WT	75.45 ± 6b	111.4 ± 1.9	174.83 ± 18.6c	121.71 ± 18.7
	KO	-	89.7 ± 6.6***	103.13 ± 16.6c**	87.71 ± 12.4a*
6W	WT	23.99 ± 11.7c	33.01 ± 4.9c	6.41 ± 0.8c	33.83 ± 2.6c
	KO	-	40.8 ± 6.4a	4.21 ± 1.3c*	44.69 ± 7*

The abundance of various cell types (NG2+, PDGFRα+, CD11b+, PDGFRβ+) in demyelinated lesions from 1-6 weeks post-lysolecithin injection is illustrated by normalizing cell density values to cell densities found in wild type mice at 1 week post-surgery (these 1 week values are designated as 100%). Values represent means ± S.D. Statistically significant differences are indicated by * < 0.05; ** < 0.01; *** < 0.001 when values were compared between WT and NG2 null mice at the same post-injection week. ^a < 0.05; ^b < 0.01; ^c < 0.001 represent statistically significant differences between values obtained for mice of the same genotype when compared to the 1^st week post-injection.